Premenopausal mammographic density in relation to cyclic variations in endogenous sex hormone levels, prolactin, and insulin-like growth factors

Cancer Research

Volumn 69, Issue 16, 2009, Pages 6490-6499

  Walker, Kate ^a   Fletcher, Olivia ^a   Johnson, Nichola ^a   Coupland, Ben ^a   McCormack, Valerie A ^a   Folkerd, Elizabeth ^b   Gibson, Lorna ^a   Hillier, Stephen G ^c   Holly, Jeff M ^d   Moss, Sue ^a   Dowsett, Mitchell ^b   Peto, Julian ^a   Silva, Isabel Dos Santos ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; ESTROGEN; ESTRONE GLUCURONIDE; PRASTERONE SULFATE; PROLACTIN; SEX HORMONE; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE;

ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BODY MASS; BREAST CANCER; CROSS-SECTIONAL STUDY; FEMALE; FOLLICULAR PHASE; HUMAN; LUTEAL PHASE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MENSTRUAL CYCLE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL; URINALYSIS; URINE LEVEL;

ADULT; BODY MASS INDEX; CALIBRATION; CROSS-SECTIONAL STUDIES; FEMALE; GONADAL STEROID HORMONES; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAMMARY GLANDS, HUMAN; MAMMOGRAPHY; MENSTRUAL CYCLE; MIDDLE AGED; PREMENOPAUSE; PROLACTIN; SOMATOMEDINS;

EID: 69249092142     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0280     Document Type: Article

References (37)

1. McCormack VA, dos Santos Silva I. Breast density and parenchymal patternsas markersof breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15:1159-69.
2. Martin LJ, Boyd NF. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res 2008;10:201.
3. Noh JJ, Maskarinec G, Pagano I, Cheung LW, Stanczyk FZ. Mammographic densities and circulating hormones: a cross-sectional study in premenopausal women. Breast 2006;15:20-8.
4. Boyd NF, Stone J, Martin LJ, et al. The association of breast mitogens with mammographic densities. Br J Cancer 2002;87:876-82.
5. Maskarinec G, Takata Y, Chen Z, et al. IGF-I and mammographic density in four geographic locations: a pooled analysis. Int J Cancer 2007;121:1786-92.
6. dos Santos Silva I, Johnson N, De Stavola B, et al. The insulin-like growth factor system and mammographic features in premenopausal and postmenopausal women. Cancer Epidemiol BiomarkersPrev 2006;15: 449-55.
7. Diorio C, Pollak M, Byrne C, et al. Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev 2005;14:1065-73.
8. Maskarinec G, Williams AE, Kaaks R. A cross-sectional investigation of breast density and insulin-like growth factor I. Int J Cancer 2003;107:991-6.
9. Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 2000;60:3744-8.
10. Lai JH, Vesprini D, Zhang W, Yaffe MJ, Pollak M, Narod SA. A polymorphic locusin the promoter region of the IGFBP3 gene isrelated to mammographic breast density. Cancer Epidemiol Biomarkers Prev 2004;13: 573-82.
11. Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L. Effect of mammographic screening from age 40 yearson breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet 2006;368: 2053-60.
12. Tanabe K, Susumu N, Hand K, Nishii K, Ishikawa I, Nozawa S. Prediction of the potentially fertile period by urinary hormone measurements using a new home-use monitor: comparison with laboratory hormone analyses. Hum Reprod 2001;16:1619-24.
13. Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ. The quantitative analysis of mammographic densities. Phys Med Biol 1994;39:1629-38.
14. Yong EL, Glasier A, Hillier H, et al. Effect of cyclofenil on hormonal dynamics, follicular development and cervical mucusin normal and oligomenorrhoeic women. Hum Reprod 1992;7:39-43.
15. Meyer PM, Zeger SL, Harlow SD, et al. Characterizing daily urinary hormone profilesfor women at midlife using functional data analysis. Am J Epidemiol 2007;165: 936-45.
16. Gunter MJ, Hoover DR, Yu H, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009;101: 48-60.
17. White E, Velentgas P , Mandelson MT, et al. Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years. J Natl Cancer Inst 1998;90:906-10.
18. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrationsof insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6.
19. Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005; 97:755-65.
20. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev 2003;24:1-27.
21. Key TJ. Serum oestradiol and breast cancer risk. Endocr Relat Cancer 1999;6:175-80.
22. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-7.
23. Tamimi RM, Byrne C, Colditz GA, Hankinson SE. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2007;99:1178-87. Epub 2007 Jul 24.
24. Group TEHaBcC. Endogenouss ex hormonesan d breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
25. Micheli A, Muti P, Secreto G, et al. Endogenouss ex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 2004;112:312-8.
26. Eliassen AH, Missmer SA, Tworoger SS, et al. Endogenouss teroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006;98:1406-15.
27. Tworoger S, Hankinson S. Prolactin and breast cancer etiology: an epidemiologic perspective. J Mammary Gland Biol Neoplasia 2008;13:41-53.
28. Page JH, Colditz GA, Rifai N, Barbieri RL, Willett WC, Hankinson SE. Plasma adrenal androgens and risk of breast cancer in premenopausal women. Cancer Epidemiol BiomarkersPrev 2004;13:1032-6.
29. Guo YP, Martin LJ, Hanna W, et al. Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev 2001;10:243-8.
30. Renehan AG, Harvie M, Howell A. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocr Relat Cancer 2006;13:273-8.
31. Allen NE, Roddam AW, Allen DS, et al. A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. Br J Cancer 2005;92:1283-7.
32. Yu H, Jin F, Shu XO, et al. Insulin-like growth factors and breast cancer risk in Chinese women. Cancer Epidemiol BiomarkersPrev 2002;11:705-12.
33. Holdaway IM, Mason BH, Lethaby AE, et al. Serum levelsof insulin-like growth factor binding protein-3 in benign and malignant breast disease. Aust N Z J Surg 1999;69:495-500.
34. Li BD, Khosravi MJ, Berkel HJ, et al. Free insulin-like growth factor-I and breast cancer risk. Int J Cancer 2001; 91:736-9.
35. Rinaldi S, KaaksR , Zeleniuch-Jacquotte A, et al. Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays. Cancer Epidemiol BiomarkersPrev 2005;14:48-52.
36. Cheetham TD, Holly JM, Baxter RC, et al. The effects of recombinant human IGF-I administration on concentrations of acid labile subunit, IGF binding protein-3, IGF-I, IGF-II and proteolysis of IGF binding protein-3 in adolescents with insulin-dependent diabetes mellitus. J Endocrinol 1998;157:81-7.
37. Boyd NF, RommensJ M, Vogt K, et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 2005;6:798-808.